Literature DB >> 24082367

Mechanisms of chronic cardiac allograft rejection.

John P Costello1, Thalachallour Mohanakumar, Dilip S Nath.   

Abstract

Chronic rejection in the form of cardiac allograft vasculopathy is one of the major factors that affects long-term graft and patient survival after heart transplantation. Whereas multiple factors contribute to the development of cardiac allograft vasculopathy, immunologic mechanisms play the predominant role in the chronic rejection process, because both alloimmune and autoimmune responses are causal factors. In addition, many nonimmune donor and recipient factors also affect the development of cardiac allograft vasculopathy, including hyperlipidemia, cytomegalovirus infection, baseline coronary artery disease, and the mechanism of brain death in the donor. Modern immunosuppression maintenance therapies have the potential to limit the development of cardiac allograft vasculopathy in the long term. Further research initiatives are needed to identify patient-specific immunosuppressive drug regimens and to elucidate factors that contribute to the chronic rejection of cardiac transplant allografts.

Entities:  

Keywords:  Arteriosclerosis/etiology; alloimmunity; autoimmunity; brain death; graft rejection, chronic/immunology/prevention & control; heart transplantation/immunology/mortality/trends; immunity, cellular; vasculopathy/cardiac allograft/cardiac transplant

Mesh:

Substances:

Year:  2013        PMID: 24082367      PMCID: PMC3783121     

Source DB:  PubMed          Journal:  Tex Heart Inst J        ISSN: 0730-2347


  39 in total

1.  The impact of mode of donor brain death on cardiac allograft vasculopathy: an intravascular ultrasound study.

Authors:  Mandeep R Mehra; Patricia A Uber; Hector O Ventura; Robert L Scott; Myung H Park
Journal:  J Am Coll Cardiol       Date:  2004-03-03       Impact factor: 24.094

2.  The Registry of the International Society for Heart and Lung Transplantation: Fourteenth Pediatric Heart Transplantation Report--2011.

Authors:  Richard Kirk; Leah B Edwards; Anna Y Kucheryavaya; Christian Benden; Jason D Christie; Fabienne Dobbels; Axel O Rahmel; Josef Stehlik; Marshall I Hertz
Journal:  J Heart Lung Transplant       Date:  2011-10       Impact factor: 10.247

3.  Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection.

Authors:  Susan Stewart; Gayle L Winters; Michael C Fishbein; Henry D Tazelaar; Jon Kobashigawa; Jacki Abrams; Claus B Andersen; Annalisa Angelini; Gerald J Berry; Margaret M Burke; Anthony J Demetris; Elizabeth Hammond; Silviu Itescu; Charles C Marboe; Bruce McManus; Elaine F Reed; Nancy L Reinsmoen; E Rene Rodriguez; Alan G Rose; Marlene Rose; Nicole Suciu-Focia; Adriana Zeevi; Margaret E Billingham
Journal:  J Heart Lung Transplant       Date:  2005-06-20       Impact factor: 10.247

Review 4.  Mechanisms of chronic rejection in cardiothoracic transplantation.

Authors:  Matthew J Weiss; Joren C Madsen; Bruce R Rosengard; James S Allan
Journal:  Front Biosci       Date:  2008-01-01

Review 5.  Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult heart transplant report--2007.

Authors:  David O Taylor; Leah B Edwards; Mark M Boucek; Elbert P Trulock; Paul Aurora; Jason Christie; Fabienne Dobbels; Axel O Rahmel; Berkeley M Keck; Marshall I Hertz
Journal:  J Heart Lung Transplant       Date:  2007-08       Impact factor: 10.247

6.  The Registry of the International Society for Heart and Lung Transplantation: 29th official adult heart transplant report--2012.

Authors:  Josef Stehlik; Leah B Edwards; Anna Y Kucheryavaya; Christian Benden; Jason D Christie; Anne I Dipchand; Fabienne Dobbels; Richard Kirk; Axel O Rahmel; Marshall I Hertz
Journal:  J Heart Lung Transplant       Date:  2012-10       Impact factor: 10.247

7.  Lumen loss in transplant coronary artery disease is a biphasic process involving early intimal thickening and late constrictive remodeling: results from a 5-year serial intravascular ultrasound study.

Authors:  H Tsutsui; K M Ziada; P Schoenhagen; A Iyisoy; W A Magyar; T D Crowe; J D Klingensmith; D G Vince; G Rincon; R E Hobbs; M Yamagishi; S E Nissen; E M Tuzcu
Journal:  Circulation       Date:  2001-08-07       Impact factor: 29.690

8.  Donor-specific HLA alloantibodies: long-term impact on cardiac allograft vasculopathy and mortality after heart transplant.

Authors:  Ingo Kaczmarek; Marcus-Andre Deutsch; Teresa Kauke; Andres Beiras-Fernandez; Michael Schmoeckel; Calin Vicol; Ralf Sodian; Bruno Reichart; Michael Spannagl; Peter Ueberfuhr
Journal:  Exp Clin Transplant       Date:  2008-09       Impact factor: 0.945

9.  Prognostic impact of microvasculopathy on survival after heart transplantation: evidence from 9713 endomyocardial biopsies.

Authors:  Nicola E Hiemann; Ernst Wellnhofer; Christoph Knosalla; Hans B Lehmkuhl; Julia Stein; Roland Hetzer; Rudolf Meyer
Journal:  Circulation       Date:  2007-08-20       Impact factor: 29.690

10.  Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation.

Authors:  Eugenia Raichlin; Jang-Ho Bae; Zain Khalpey; Brooks S Edwards; Walter K Kremers; Alfredo L Clavell; Richard J Rodeheffer; Robert P Frantz; Charanjit Rihal; Amir Lerman; Sudhir S Kushwaha
Journal:  Circulation       Date:  2007-11-19       Impact factor: 29.690

View more
  27 in total

1.  Acute pump failure of the transplanted heart: diagnostic and therapeutic challenges.

Authors:  L Maximilian Buja
Journal:  Tex Heart Inst J       Date:  2013

2.  Cardiac allograft vasculopathy: a complex multifactorial sequela of heart transplantation.

Authors:  Ana Maria Segura; L Maximilian Buja
Journal:  Tex Heart Inst J       Date:  2013

3.  Complement C5 Inhibition Reduces T Cell-Mediated Allograft Vasculopathy Caused by Both Alloantibody and Ischemia Reperfusion Injury in Humanized Mice.

Authors:  L Qin; G Li; N Kirkiles-Smith; P Clark; C Fang; Y Wang; Z-X Yu; D Devore; G Tellides; J S Pober; D Jane-Wit
Journal:  Am J Transplant       Date:  2016-06-14       Impact factor: 8.086

Review 4.  What's new in clinical solid organ transplantation by 2013.

Authors:  Maurizio Salvadori; Elisabetta Bertoni
Journal:  World J Transplant       Date:  2014-12-24

5.  De novo expression of fetal ED-A(+) fibronectin and B (+) tenascin-C splicing variants in human cardiac allografts: potential impact for targeted therapy of rejection.

Authors:  Marcus Franz; Monika Matusiak-Brückner; Petra Richter; Katja Grün; Barbara Ziffels; Dario Neri; Hansjörg Maschek; Uwe Schulz; Alexander Pfeil; Christian Jung; Hans R Figulla; Jan Gummert; Alexander Berndt; André Renner
Journal:  J Mol Histol       Date:  2014-05-03       Impact factor: 2.611

Review 6.  The Evaluation and Therapeutic Management of Hypertension in the Transplant Patient.

Authors:  Beje Thomas; Matthew R Weir
Journal:  Curr Cardiol Rep       Date:  2015-11       Impact factor: 2.931

Review 7.  Human leukocyte antigens and alloimmunization in heart transplantation: an open debate.

Authors:  Antonietta Picascia; Vincenzo Grimaldi; Amelia Casamassimi; Maria Rosaria De Pascale; Concetta Schiano; Claudio Napoli
Journal:  J Cardiovasc Transl Res       Date:  2014-09-05       Impact factor: 4.132

8.  Thalidomide treatment prevents chronic graft rejection after aortic transplantation in rats - an experimental study.

Authors:  Katharine K Miller; Dong Wang; Xiaomeng Hu; Xiaoqin Hua; Tobias Deuse; Evgenios Neofytou; Thomas Renne; Joachim Velden; Hermann Reichenspurner; Sonja Schrepfer; Daniel Bernstein
Journal:  Transpl Int       Date:  2017-08-14       Impact factor: 3.782

9.  Hyperlipidemia and Allograft Rejection.

Authors:  Jessamyn Bagley; Linus Williams; Michael Hyde; Christian Rosa Birriel; John Iacomini
Journal:  Curr Transplant Rep       Date:  2019-02-26

10.  Dipeptidyl Peptidase-4 Inhibitor Decreases Allograft Vasculopathy Via Regulating the Functions of Endothelial Progenitor Cells in Normoglycemic Rats.

Authors:  Feng-Yen Lin; Chun-Min Shih; Chun-Yao Huang; Yi-Tin Tsai; Shih-Hurng Loh; Chi-Yuan Li; Cheng-Yen Lin; Yi-Wen Lin; Chien-Sung Tsai
Journal:  Cardiovasc Drugs Ther       Date:  2021-12       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.